HydRegen
Enzyme-based biocatalysts for cleaner, safer, and more efficient chemical manufacturing.
Website: https://hydregenoxford.com
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | HydRegen |
| Tagline | Enzyme-based biocatalysts for cleaner, safer, and more efficient chemical manufacturing. |
| Headquarters | Oxford, UK [Crunchbase] |
| Founded | 2021 [Department of Chemistry, 2026] |
| Stage | Series A [Business Wire, October 2026] |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout [Department of Chemistry, 2026] |
| Funding Label | Series A |
| Total Disclosed | ~$8,000,000 [Business Wire, October 2026] |
Links
Open sources
- Website: https://hydregenoxford.com
What an Investor Needs First
PUBLIC HydRegen is an Oxford spinout building enzyme-based catalysts for chemical manufacturing, and it merits investor attention now because it has moved from research-backed platform development into a newly announced $8 million Series A intended to support commercial scale-up across pharmaceutical, specialty chemical, agrochemical, materials, and bulk chemical markets [Business Wire, October 2026] [Department of Chemistry, 2026]. The company was founded in 2021 by Professor Kylie Vincent and Dr Holly Reeve out of University of Oxford research, with prior underlying work that Begbroke Science Park said attracted roughly £3 million of grant funding over five years before commercialization, which suggests a long technical gestation rather than a fast-formed venture thesis [Department of Chemistry, 2026] [Begbroke Science Park, June 2026].
The product case rests on Bio2Amine and related hydrogen-driven biocatalytic processes that aim to replace precious-metal hydrogenation catalysts with enzyme-based alternatives while fitting into existing manufacturing infrastructure, a point the company has repeated across financing and corporate materials [HydRegen, March 2022] [HydRegen, Unknown] [Business Wire, October 2026]. That integration claim is strategically important because customer adoption in process chemistry often stalls when a new technology requires plant redesign, though the reported economic upside, including up to 40 percent cost-effectiveness improvement, remains largely company-stated and should be treated as directional until validated in named production settings [HydRegen, September 2025] [Business Wire, October 2026] [The National Law Review, 2026].
Leadership appears credible for the science-commercialization handoff: Reeve is identified as CEO and co-founder leading commercial and fundraising work, while Vincent brings the academic chemistry base from which the company emerged [Begbroke Science Park, June 2026] [Holly Reeve - HydRegen Limited | LinkedIn, 2026] [EnSpire Oxford, 2026]. The capital stack is also becoming clearer, with early backing from the UK Innovation & Science Seed Fund in 2022 and a Series A led by Genoa Ventures with participation from Clean Growth Fund, First Imagine! Ventures, Oxford Technology Management, Headington Holdings, Oxonian, Foxglove Capital, and Rapid Innovation Group, all consistent with a venture-scale B2B deeptech path rather than grant dependence alone [HydRegen, March 2022] [Business Wire, October 2026].
Over the next 12 to 18 months, the key watchpoints are whether HydRegen can convert collaborations into repeatable revenue, produce independent proof of process economics and emissions reduction, and show that programs such as the Innovate UK-backed AM Technology collaboration translate into customer deployments beyond pilot-stage chemistry work [HydRegen, July 2024] [HydRegen, September 2025]. The setup is promising, but the underwriting still turns on commercial evidence rather than scientific novelty alone.
Partially corroborated -- Core company identity, founding, and financing are corroborated by University of Oxford, Begbroke Science Park, and Business Wire, but several product-performance claims remain company-stated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Series A, total disclosed approximately $8,000,000 |
Inside the Company
Open sources HydRegen sits in a part of industrial biotech where the scientific origin matters as much as the commercial pitch. The company was founded in 2021 in Oxford, UK, and traces its origin to University of Oxford research led by Professor Kylie Vincent and Dr Holly Reeve [Crunchbase] [HydRegen, September 2025]. Public materials describe it as an Oxford spinout developing enzyme-based biocatalytic hydrogenation processes for chemical manufacturing, with Bio2Amine named as its core platform in early company communications [Crunchbase] [HydRegen, March 2022].
The milestones that are visible in public sources suggest a company that spent its first years converting lab work into funded industrial programs rather than racing to broad market claims. In March 2022, HydRegen announced £385,000 of seed funding led by the UK Innovation & Science Seed Fund and said it was partnering with pharmaceutical and fine-chemical companies on lower-cost manufacturing processes [HydRegen, March 2022]. By July 2024, the company was pointing to an Innovate UK-backed collaboration with AM Technology around scaling Bio2Amine for a paracetamol intermediate and another active pharmaceutical ingredient, with the project valued at more than £0.9 million according to the company [HydRegen, July 2024].
A second phase appears in 2025 and 2026, when the company began to look more like a formal scale-up. HydRegen announced Kevin Matthews as chair in September 2025 [HydRegen, September 2025]. On October 14, 2026, it announced an $8 million Series A led by Genoa Ventures, with participation from Clean Growth Fund and First Imagine! Ventures and support from several Oxford-linked backers, according to the financing release [HydRegen, September 2025] [HydRegen, March 2022] [Crunchbase].
Partially corroborated -- Grounded in Crunchbase and company website materials, with chronology partly dependent on company-issued announcements.
Under the Hood
Reported and inferred
HydRegen is pursuing a fairly specific technical wedge, not a general sustainability story. Public materials describe an enzyme-based biocatalysis platform for chemical manufacturing, with the core claim that it can replace precious-metal hydrogenation catalysts in existing industrial processes rather than forcing customers to redesign plants from scratch [HydRegen, March 2022] [HydRegen] [The National Law Review, 2026]. The company’s best-documented product name is Bio2Amine™, which HydRegen says uses hydrogen gas rather than glucose as the energy source for biocatalysis [HydRegen, March 2022]. University of Oxford materials and founder-linked profiles describe the underlying approach in more technical terms, including hydrogen-driven biocatalysis using enzyme-modified carbon particles, enzymes on carbon beads, and operation of biocatalytic reactions in continuous flow [University of Oxford] [LinkedIn, 2026].
The public record also suggests the platform is being aimed at fine-chemical and pharmaceutical synthesis first, then adjacent process chemistry categories. HydRegen has said it is applying Bio2Amine in work on a paracetamol intermediate and another active pharmaceutical ingredient through an Innovate UK-funded collaboration with AM Technology valued at more than £0.9 million [HydRegen, July 2024], and Business Wire's financing coverage says the company is targeting pharmaceutical, specialty-chemical, agrochemical, materials, and bulk-chemical manufacturers [Business Wire, October 2026]. A separate Oxford chemistry source says the company has extended its approach to selective biocatalytic deuterium insertion, which matters because deuterated compounds can be relevant in medicinal chemistry workflows, although the commercial status of that capability is not established in the cited material [University of Oxford].
The harder point is validation. HydRegen and syndication coverage repeat claims of up to 40 percent cost improvement and lower carbon emissions, with one company source stating 40 to 50 percent cost savings and another claiming at least 3x CO2e benefit [Business Wire, October 2026] [HydRegen, September 2025] [HydRegen, July 2024]. Those figures should be read as company-stated performance ranges rather than independently benchmarked outcomes. On stack and team buildout, job postings indicate current hiring around chemistry R&D and microbial strain engineering, which supports a reading that the company is building both catalyst development and strain-engineering capacity, but any fuller tech-stack description would be speculative and is therefore best treated as limited inference from hiring signals (inferred from job postings) [Jobsora] [Cranleigh STEM].
Partially corroborated -- Core product positioning is corroborated by HydRegen materials, Business Wire financing coverage, and Oxford-linked sources, but most performance claims remain company-stated rather than independently validated.
Market Research
PUBLIC
The market matters now because chemical manufacturers are under simultaneous pressure to cut process cost, reduce carbon intensity, and avoid plant redesign, which is precisely the wedge HydRegen says its enzyme-based hydrogenation platform addresses [Business Wire, October 2026] [The National Law Review, 2026].
The public record does not provide a direct third-party TAM, SAM, or SOM for HydRegen itself, so the evidence has to be handled more narrowly. What is documented is the set of end markets the company is pursuing: pharmaceuticals, specialty chemicals, agrochemicals, materials, and bulk chemicals [Business Wire, October 2026]. That matters because the addressable opportunity is not a single product market in the software sense, but a process-technology layer that could attach to multiple chemical value chains where hydrogenation or related redox steps are cost, yield, safety, or emissions bottlenecks [Department of Chemistry, 2026] [The National Law Review, 2026].
The nearer-term commercial logic appears tighter than the broad category language. HydRegen has publicly pointed to work on a paracetamol intermediate and another active pharmaceutical ingredient through an Innovate UK-funded collaboration with AM Technology valued at more than £0.9 million, alongside a separate collaboration in hair dyes moving into its next phase ahead of schedule, according to company statements [HydRegen, July 2024] [HydRegen, September 2025]. That suggests the initial obtainable market is more likely to emerge from fine chemicals and selected specialty applications, where process changes can be evaluated reaction by reaction, before any broader push into larger-volume commodity settings.
The demand drivers in the cited record are fairly consistent even when the numbers are still mostly company-provided. HydRegen and financing coverage describe a proposition built around lower-cost manufacturing, lower carbon emissions, and compatibility with existing production infrastructure, including claims that the technology can make chemical manufacturing up to 40 percent more cost-effective and drop into existing plant infrastructure without redesign [Business Wire, October 2026] [The National Law Review, 2026] [HydRegen, September 2025]. For buyers, that combination matters because retrofittable process improvements usually face a lower adoption hurdle than technologies that require a new plant, a full equipment swap, or a change in feedstock logistics. The external corroboration is still limited, but the direction of demand is plausible and well aligned with how industrial customers typically screen process technology, namely capex avoidance, operating savings, and regulatory resilience.
Adjacent and substitute markets are easier to identify than direct market size. The most immediate substitute is conventional hydrogenation using precious-metal catalysts, which HydRegen explicitly positions against [HydRegen, Unknown]. A second adjacent market is conventional biocatalysis powered by glucose rather than hydrogen gas, since HydRegen says Bio2Amine uses hydrogen as the energy source for biocatalysis [HydRegen, March 2022]. In practice, that means the company is not only competing for budget inside green chemistry or industrial biotech programs, but also against incumbent chemistry routes that may already be validated, depreciated, and deeply embedded in customer plants.
Regulatory and macro forces appear supportive, even if the source set here is more directional than quantitative. The company and third-party coverage repeatedly frame the technology around safer and cleaner chemical manufacturing, reduced use of finite resources, and lower energy demands under milder biological conditions [Business Wire, October 2026] [HydRegen, Summer 2024]. In the UK context, the presence of Innovate UK-backed work and the Oxford spinout pathway indicates that public-sector commercialization support remains part of the market fabric for this category [HydRegen, July 2024] [Department of Chemistry, 2026]. The practical reading is that decarbonization policy, industrial efficiency mandates, and supply concerns around precious metals can all strengthen the case for alternatives, but proof of demand will still depend on customer validation at manufacturing scale rather than policy alignment alone.
| Market lens | Public evidence | Why it matters |
|---|---|---|
| End markets pursued | Pharmaceuticals, specialty chemicals, agrochemicals, materials, and bulk chemicals [Business Wire, October 2026] | Indicates a cross-vertical process technology market rather than a single-sector product market. |
| Near-term application evidence | Paracetamol intermediate and another API in AM Technology collaboration valued at more than £0.9 million [HydRegen, July 2024] | Points to fine chemical and pharma process development as an early commercialization wedge. |
| Substitute market | Precious-metal hydrogenation catalysts [HydRegen, Unknown] | Frames the incumbent budget line HydRegen is trying to displace. |
| Adoption tailwind | Integration into existing manufacturing infrastructure [HydRegen, September 2025] [The National Law Review, 2026] | Suggests lower capex friction than a greenfield process change. |
The table shows a market thesis built less on top-down sizing and more on where process pain is acute enough to justify change. For now, the best-supported read is that HydRegen is targeting a broad industrial chemistry opportunity through a narrow initial wedge in fine chemicals and pharmaceutical intermediates.
Partially corroborated -- Section relies on one independent financing report and one independent legal publication, with several material market assertions still sourced to company statements.
Competition and Substitutes
MIXED HydRegen is positioned less against a single named startup rival in the source set than against the installed chemistry stack, namely precious-metal hydrogenation catalysts and conventional metal-catalyzed process chemistry that already sits inside pharmaceutical, specialty-chemical, agrochemical, materials, and bulk-chemical manufacturing lines [HydRegen, Unknown] [Business Wire, October 2026].
The competitive map therefore has to be read by layer rather than by cap table. At the incumbent layer, HydRegen is trying to displace precious-metal hydrogenation catalysts with enzyme-based biocatalysts, a direct substitution claim that appears in company materials and is repeated in publisher-distributed financing coverage [HydRegen, Unknown] [Business Wire, October 2026]. At the adjacent-substitute layer, the company is also competing with established redox biocatalysis workflows that use glucose as the energy source, because Bio2Amine™ is described as using hydrogen gas instead of glucose for biocatalysis [HydRegen, March 2022]. At the process-integration layer, the alternative is not only another catalyst but a customer decision to keep existing validated chemistry unchanged, particularly in regulated end markets where manufacturing changes can be slow and evidence-heavy [Business Wire, October 2026] [The National Law Review, 2026].
HydRegen's clearest edge today is technical fit with existing infrastructure, if the public claims hold up under customer diligence. The company says its technology can be integrated into customers' existing manufacturing infrastructure, and publisher coverage similarly describes the enzyme-based catalysts as dropping into existing plant infrastructure without redesign [HydRegen, September 2025] [The National Law Review, 2026]. For a process-chemistry buyer, that matters more than a broad sustainability claim, because retrofitting a plant or revalidating an entirely new route is usually a slower sell than replacing a catalyst within a familiar production environment. That edge looks real enough to merit attention, but it is also perishable: if incumbent catalyst suppliers or larger bioprocess groups can offer comparable drop-in performance, HydRegen does not yet have public evidence of a distribution moat, a large installed customer base, or regulatory exclusivity that would keep copycats out [Business Wire, October 2026].
The company's second edge is founder-market fit rooted in Oxford chemistry research rather than commercial channel control. HydRegen was founded in 2021 by Professor Kylie Vincent and Dr Holly Reeve, and the underlying work reportedly generated about £3 million in grant funding over five years before spinout activity [Department of Chemistry, 2026] [Begbroke Science Park, June 2026]. Public materials also describe hydrogen-driven biocatalysis using enzyme-modified carbon particles and continuous-flow biocatalytic reactions, which suggests the company is built on a technically differentiated research base rather than simple formulation work [Vincent group - University of Oxford, 2026] [Department of Chemistry, 2026]. Still, durability here depends on whether that research position converts into protected process know-how, customer-specific validation data, and repeatable scale-up. The open sources do not establish those later-stage defenses.
The main exposure is straightforward: larger incumbents already own customer relationships, procurement pathways, and validation budgets, while HydRegen appears to be earlier in commercial proof. Public evidence points to collaborations in paracetamol intermediates, hair dyes, and a strategic collaboration with James Robinson Speciality Ingredients, but it does not identify a broad roster of production customers or long-term volume contracts [HydRegen, July 2024] [HydRegen, September 2025] [HydRegen, Unknown]. That leaves the company vulnerable if established catalyst suppliers, contract manufacturers, or better-capitalized process-technology vendors can match the cost and carbon case with lower switching risk. It also limits HydRegen's reach into segments where customers may prefer full-process outsourcing or bundled chemistry solutions rather than a catalyst platform alone [Business Wire, October 2026].
Over the next 18 months, the most plausible competitive scenario is not winner-take-all but a race for validated reference processes in a few commercially relevant molecules. HydRegen is the clearest winner if customers continue to prioritize drop-in decarbonization inside existing flow hydrogenation infrastructure, because that is the company's stated wedge and the point on which several public descriptions converge [HydRegen, September 2025] [The National Law Review, 2026]. The likely loser if buyers instead favor incumbent metal-catalyst routes and defer process change is the broader enzyme-substitution category, with HydRegen the most visible named company in this source set and therefore the one most exposed to slow adoption [HydRegen, Unknown] [Business Wire, October 2026]. With no named startup peers in the provided research, the immediate contest appears to be adoption versus inertia, not a clean head-to-head startup battle.
Partially corroborated -- This section relies on a mix of company materials, publisher-distributed financing coverage, and Oxford-affiliated research pages.
Opportunity
PUBLIC
If HydRegen executes, the prize is not a niche process-improvement business but a credible shot at becoming a preferred decarbonization layer for hydrogenation and related redox steps across multiple chemical end markets, a part of manufacturing where incumbent methods are costly, emissions-intensive, and deeply embedded in existing plants [Business Wire, October 2026] [HydRegen, March 2022] [The National Law Review, 2026].
The headline opportunity is straightforward. HydRegen is trying to sell a way for chemical manufacturers to swap out precious-metal or conventional catalytic steps for enzyme-based biocatalysts without rebuilding the plant around them, which matters because capital projects are often the hidden blocker in industrial adoption [HydRegen company news] [HydRegen, September 2025] [The National Law Review, 2026]. That outcome is still early rather than proven, but it is not purely aspirational on the evidence available: the company has moved from University of Oxford research into a 2021 spinout, raised seed funding in 2022, reported joint work with pharmaceutical and fine-chemical companies, named AM Technology and JRSI as collaborators, and closed an $8 million Series A led by Genoa Ventures in October 2026 to expand work with existing pharmaceutical and specialty-chemical customers while pushing into agrochemicals, materials, and bulk chemicals [Department of Chemistry, 2026] [HydRegen, March 2022] [HydRegen, July 2024] [HydRegen company news] [Business Wire, October 2026]. In plain terms, the company has advanced far enough to show that the commercial wedge is a manufacturing retrofit story, not only a lab story.
The pathways to scale are narrower than software investors may prefer, but they are legible if process validation continues.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Pharma process wedge | HydRegen wins recurring revenue by replacing incumbent hydrogenation steps in selected active pharmaceutical ingredient and intermediate routes, then expands from one validated process to adjacent molecules at the same customer | The AM Technology collaboration around a paracetamol intermediate and another API demonstrates a named scale-up effort, while the Series A is earmarked in part for expansion with existing pharmaceutical customers [HydRegen, July 2024] [Business Wire, October 2026] | Pharmaceutical and fine-chemical companies were already cited as collaborators in 2022, and paracetamol was described by the company in 2025 as its first customer process taking centre stage [HydRegen, March 2022] [HydRegen, September 2025] |
| Cross-vertical catalyst platform | The company turns Bio2Amine into a broader licensing and joint-development platform used across specialty chemicals, dyes, materials, and selected bulk-chemical applications | Adoption outside pharma becomes easier if the core claim holds that the technology integrates into existing manufacturing infrastructure and can lower cost while reducing emissions [HydRegen, September 2025] [Business Wire, October 2026] | HydRegen already describes target sectors beyond pharma, including specialty chemicals, agrochemicals, materials, and bulk chemicals, and also cited a second customer collaboration in hair dyes [Business Wire, October 2026] [HydRegen, September 2025] |
| Hydrogen-driven biocatalysis standard | HydRegen's approach becomes a recognized process standard for cases where manufacturers want biological selectivity without the glucose-driven economics or process constraints of traditional biocatalysis | Continued demonstration that hydrogen gas can serve as the energy source for biocatalysis in continuous-flow settings, paired with customer proof points, could distinguish the platform on process economics [HydRegen, March 2022] [Department of Chemistry, 2026] | The underlying scientific approach is not described as a one-off reaction: Oxford-linked materials point to H2-driven biocatalysis using enzyme-modified carbon particles, continuous-flow operation across many reactions, and extension into selective deuterium insertion [Vincent group - University of Oxford, 2026] [Department of Chemistry, 2026] |
The compounding mechanism here is process reuse. If one manufacturer validates HydRegen on a high-volume intermediate, the company should gain reaction data, operating know-how in flow, a stronger case for regulator and quality teams, and a cleaner template for the next customer pursuing a similar transformation, especially if the same enzyme-on-particle architecture can be tuned across reaction classes [Department of Chemistry, 2026] [Vincent group - University of Oxford, 2026]. That is not a consumer-style network effect, but it can still compound: each successful deployment may reduce the commercial burden of proving retrofit feasibility, while each collaboration broadens the company's credibility as a partner for joint development rather than a pure reagent vendor [HydRegen, July 2024] [HydRegen company news] [Business Wire, October 2026]. The early signs of this loop are modest but visible in the move from grant-backed research, to seed-backed commercialization, to named industrial collaborations, to a Series A framed around scaling with existing customers [Begbroke Science Park, June 2026] [HydRegen, March 2022] [Business Wire, October 2026].
Sizing the win is the least certain part because no independent market-size figure or clean public comparable is provided in the source set. Even so, the upside can be stated in scenario terms. If the cross-vertical catalyst-platform scenario plays out, and HydRegen becomes a repeat licensing and process-development supplier across pharmaceutical, specialty-chemical, and selected bulk-chemical workflows, it could plausibly grow into an industrial-biotech platform of strategic value to larger chemical or life-sciences incumbents, especially given the sector breadth cited in the Series A announcement and the company's retrofit positioning [Business Wire, October 2026] [The National Law Review, 2026]. That is a scenario, not a forecast, and the absence of disclosed revenue, deployment scale, or third-party market sizing means the upside case rests more on category logic than on benchmarked financial modeling.
Partially corroborated -- Built from a mix of company statements, University of Oxford materials, and financing coverage; the existence of the company, founding, funding, and named collaborations are corroborated, but customer outcomes and economic benefits remain partly company-sourced.
Sources
Open sources
[Crunchbase] HydRegen | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/hydregen
[Department of Chemistry, 2026] The Story of HydRegen | Department of Chemistry | https://www.chem.ox.ac.uk/article/the-story-of-hydregen
[Business Wire, October 2026] HydRegen Raises $8M (£6M) Series A to Bring Biocatalysis to Industrial Chemical Manufacturing | https://www.businesswire.com/news/home/20261013479255/en/HydRegen-Raises-$8M-%C2%A36M-Series-A-to-Bring-Biocatalysis-to-Industrial-Chemical-Manufacturing
[Begbroke Science Park, June 2026] Tenant Spotlight: HydRegen | https://www.begbroke.ox.ac.uk/news/tenant-spotlight-hydregen/
[HydRegen, March 2022] HydRegen announces new funding and partnership | https://hydregenoxford.com/news/hydregen-announces-new-funding-and-partnership
[HydRegen, September 2025] HydRegen welcomes Kevin Matthews as Chair to drive the next chapter of growth | https://hydregenoxford.com/news/hydregen-welcomes-kevin-matthews-as-chair-to-drive-the-next-chapter-of-growth
[The National Law Review, 2026] HydRegen Raises $8M (£6M) Series A to Bring Biocatalysis to Industrial Chemical Manufacturing | https://www.natlawreview.com/article/hydregen-raises-8m-6m-series-bring-biocatalysis-industrial-chemical-manufacturing
[Holly Reeve - HydRegen Limited | LinkedIn, 2026] Holly Reeve - HydRegen Limited | LinkedIn | https://www.linkedin.com/in/holly-reeve-83907061/
[EnSpire Oxford, 2026] Meet the innovators of the future | https://enspireoxford.com/meet-the-innovators-of-the-future/
[HydRegen] HydRegen company news | https://hydregenoxford.com/news
[University of Oxford] The Story of HydRegen | Department of Chemistry | https://www.chem.ox.ac.uk/article/the-story-of-hydregen
[LinkedIn, 2026] Holly Reeve - HydRegen Limited | LinkedIn | https://www.linkedin.com/in/holly-reeve-83907061/
[Jobsora] Analytical Development Chemist jobs in Oxford | https://uk.jobsora.com/jobs-analytical-development-chemist-oxford
[Cranleigh STEM] Microbial Strain Engineer | https://www.cranleighstem.co.uk/opportunities/microbial-strain-engineer-8647
[HydRegen, July 2024] A year of success | https://hydregenoxford.com/news/a-year-of-success
[HydRegen, Summer 2024] A year of success | https://hydregenoxford.com/news/a-year-of-success
[Vincent group - University of Oxford, 2026] Vincent Group | University of Oxford | https://vincent.chem.ox.ac.uk/
[HydRegen company news] HydRegen company news | https://hydregenoxford.com/news
Articles about HydRegen
- HydRegen Replaces Precious Metal Catalysts With Enzymes on Carbon Beads — The Oxford spinout's $8 million Series A, led by Genoa Ventures, backs a 'slot in' technology promising cost and carbon savings for pharmaceutical and specialty chemical makers.